Anzeige
Meldung des Tages: Lithium ist zurück — und diesmal führen Institutionen den Markt an

Jazz Pharmaceuticals Aktie News

Aktie
WKN:  A1JS1K ISIN:  IE00B4Q5ZN47 US-Symbol:  JAZZ Branche:  Biotechnologie Land:  Irland
142,65 €
+0,00 €
0,00%
16:45:32 Uhr
Depot/Watchlist
Marktkapitalisierung *
8,78 Mrd. €
Streubesitz
-
KGV
-
neu: Nachhaltigkeits-Score
37 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,55: JZ1P47
Werbung

Jazz Pharmaceuticals News

20.08.25 - PR Newswire
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 PR Newswire
20.08.25 - PR Newswire
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 PR Newswire
20.08.25 - PR Newswire
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 PR Newswire
06.08.25 - PR Newswire
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma PR Newswire
05.08.25 - PR Newswire
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
05.08.25 - PR Newswire
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
22.07.25 - PR Newswire
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 PR Newswire
22.07.25 - PR Newswire
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 PR Newswire
10.07.25 - PR Newswire
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer PR Newswire
10.07.25 - PR Newswire
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer PR Newswire
01.07.25 - PR Newswire
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer PR ...
10.06.25 - PR Newswire
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-​Line Maintenance Treatment of Extensive-​Stage Small Cell Lung ...
09.06.25 - PR Newswire
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
Jazz Pharmaceuticals Presents Late-​Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in ...
02.06.25 - PR Newswire
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-​Line Maintenance Therapy for ...
02.06.25 - PR Newswire
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-​hrii) in First-​Line HER2-Positive Metastatic ...
29.05.25 - PR Newswire
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in ...
21.05.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences PR Newswire
21.05.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences PR Newswire
06.05.25 - PR Newswire
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
06.05.25 - PR Newswire
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »
Anzeige

Aktie im Fokus

GOLD-AUSBRUCH
GMV Minerals
0,187 €
+13,3%
GMV Minerals Chart
Von der PEA zum Milliarden-Potenzial
Mehr zur Aktie »